We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Multitargeted bioactive ligands for PPARs discovered in the last decade.
- Authors
Zhang, Jun; Liu, Xin; Xie, Xian ‐ Bin; Cheng, Xian ‐ Chao; Wang, Run ‐ Ling
- Abstract
Type 2 diabetes took insulin resistance as the main clinical manifestation. PPARs have been reported to be the therapeutic targets of metabolic disorders, such as obesity, hypertension, diabetes, and cardiovascular disease. Previously, PPARγ agonist rosiglitazone was restricted in clinic due to cardiomyocytes infarction, weight gain, and other serious side-effects, which were mainly due to the single and selective PPARγ agonism. In recent years, multitarget-directed PPAR agonists with synergistic reaction as well as fewer side-effect have been the hot topic in designing promising agents. In this review, we updated and generalized the development of PPARγ partial agonists, PPARγ antagonists, PPARα/γ dual agonists, PPARδ partial agonists, PPARδ antagonists, PPARα/δ dual agonists, PPARγ/δ dual agonists, and PPARα/γ/δ pan-agonists published in recent decade. Most of these molecules were modified from known structures or came from high-throughput screening. Among these molecules, some were expected to be promising drugs against metabolic disorders, while others seemed to provide new insight for designing novel PPAR agents.
- Subjects
TYPE 2 diabetes; INSULIN resistance; METABOLIC disorders; ROSIGLITAZONE; HYPERGLYCEMIA
- Publication
Chemical Biology & Drug Design, 2016, Vol 88, Issue 5, p635
- ISSN
1747-0277
- Publication type
Article
- DOI
10.1111/cbdd.12806